These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 8608043)
61. Critically appraised paper: Exercise is safe, clinically effective and cost-effective compared to usual care after non-reconstructive breast cancer surgery [commentary]. McNeely ML; Parkinson J J Physiother; 2022 Apr; 68(2):145. PubMed ID: 35396172 [No Abstract] [Full Text] [Related]
62. Correction: The effect of cognitive behavioral therapy on the quality of life of breast cancer patients: a systematic review and meta‑analysis of randomized controlled trials. Getu MA; Chen C; Panpan W; Mboineki JF; Dhakal K; Du R Qual Life Res; 2022 Oct; 31(10):3089. PubMed ID: 35972619 [No Abstract] [Full Text] [Related]
63. A review of the effectiveness of early treatment in breast cancer. KRAUS AS Surg Gynecol Obstet; 1953 May; 96(5):545-52. PubMed ID: 13056884 [No Abstract] [Full Text] [Related]
66. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective? Naeim A; Keeler EB Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407 [TBL] [Abstract][Full Text] [Related]
67. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753 [TBL] [Abstract][Full Text] [Related]
68. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524 [TBL] [Abstract][Full Text] [Related]
69. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447 [TBL] [Abstract][Full Text] [Related]
70. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. Liberato NL; Marchetti M; Barosi G J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267 [TBL] [Abstract][Full Text] [Related]
71. Cost effectiveness and other assessments of adjuvant therapies for early breast cancer. Hillner BE; Smith TJ Oncology (Williston Park); 1995 Nov; 9(11 Suppl):129-34. PubMed ID: 8608043 [TBL] [Abstract][Full Text] [Related]
72. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal]. Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267 [TBL] [Abstract][Full Text] [Related]
73. Adjuvant therapy for breast cancer. NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506 [TBL] [Abstract][Full Text] [Related]